---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009600"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:06:07.076347+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience reports FY2022 cash $34.7M; XACIATO first commercial sale expected Q2 2023

## Summary
- Cash and cash equivalents $34.7M at Dec 31, 2022, down from $51.7M at Dec 31, 2021.
- G&A expenses $11.2M (FY2022) vs $8.4M (FY2021); R&D expenses $30.0M vs $30.6M.
- Received $24.1M in non-dilutive funding in 2022: $10M from Organon license, $13.3M grants, $0.8M Australian rebate.
- XACIATO first commercial sale expected Q2 2023, triggering $2.5M milestone to Dare.
- Sildenafil Cream Phase 2b topline data targeted for Q2 2023; Ovaprene pivotal study initiation mid-2023.

## SEC filing metadata
- accession: 0001493152-23-009600
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/0001493152-23-009600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009600
- JSON: https://secwatch.observer/filing/0001493152-23-009600.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009600.txt

## Key facts
- Earnings Releases
  Dare Bioscience, Inc. reported financial results for the quarter and fiscal-year ended December 31, 2022.
  - Period: the quarter and fiscal-year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Daré Bioscience, Inc. issued a press release announcing its financial results for the quarter and fiscal-year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315223009600/0001493152-23-009600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.